Sign In
Buy BNTX
$88.45
-0.690 (-0.774%)
At Close: Jun 03, 2026
3 Pharma Stocks to Sell in February Before They Crash and Burn
02:39pm, Friday, 02'nd Feb 2024
The pharma industry has developed some real blockbusters between novel vaccines and weight loss drugs over the past few years. This has increasingly led investors to view pharma stocks as a promising
Top 10 stocks to buy in 2024
07:41pm, Tuesday, 16'th Jan 2024
2023 was an incredibly strong year for U.S. stocks but many believe the S&P 500 will push further up in the new year. To play that continued strength, our experts have picked top 10 stocks to buy in 2
BioNTech SE (BNTX) 42nd Annual J.P. Morgan Healthcare Conference (Transcript)
03:00pm, Tuesday, 09'th Jan 2024
BioNTech SE (BNTX) 42nd Annual J.P. Morgan Healthcare Conference (Transcript)
BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics
01:57am, Thursday, 28'th Dec 2023
BioNTech is diversifying its portfolio beyond its COVID-19 vaccine, focusing on antibody-drug conjugates (ADCs) and novel vaccines. The company has acquired MediLink Therapeutics' ADC technology and i
BioNTech's COVID-19 Success Paves The Way For A Strong Drug Pipeline
06:45am, Saturday, 23'rd Dec 2023
BioNTech and Pfizer's COVID-19 vaccine, COMIRNATY, generated $36.8 billion in sales in 2021, making it the highest-selling pharmaceutical product in a single year. BioNTech's stock has faced challenge
3 Stocks Down 30% or More This Year That Wall Street Expects to Skyrocket in 2024
05:50am, Monday, 18'th Dec 2023
BioNTech's pipeline should take center stage going forward. JD.com is dirt cheap after a big sell-off.
Barron's Favorite 10 Stocks for 2024
11:44am, Friday, 15'th Dec 2023
Barron's annual list of unloved stocks ranges from tech giant Alibaba to miner Barrick to auto rental stalwart Hertz Global.
BioNTech Vs. Moderna: Navigating The mRNA Landscape
07:55am, Wednesday, 22'nd Nov 2023
Moderna and BioNTech are pioneering companies in mRNA technology, known for their fast development of highly effective COVID-19 vaccines. Both companies have the potential to transform the treatment l
BioNTech says European Patent Office has declared Moderna patent invalid
05:52am, Tuesday, 21'st Nov 2023
COVID-19 vaccine maker BioNTech said on Tuesday the European Patent Office has declared as invalid an mRNA patent that has been invoked by Moderna in litigation about alleged an patent violation by Bi
3 Biotech Stocks You'll Regret Not Buying Soon: November 2023
04:17pm, Tuesday, 14'th Nov 2023
Biotechnology is a booming industry recently focused on synthetic biology, biomanufacturing and gene editing. Biotech is seen as the key to the future, as it has the potential to cure diseases and sav
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
10:01pm, Thursday, 09'th Nov 2023
Amid some rising questions for the economy, value-seeking investors may want to consider underappreciated biotech stocks. As a sector that, while not immune to broader pressures, generally manages to
BioNTech SE (BNTX) Q3 2023 Earnings Call Transcript
12:17pm, Monday, 06'th Nov 2023
BioNTech SE (NASDAQ:BNTX ) Q3 2023 Earnings Call Transcript November 8, 2023 8:00 AM ET Company Participants Victoria Meissner - VP, Strategy & IR Ugur Sahin - Co-Founder & CFO Ozlem Tureci - Chief Me
BioNTech Posts a Profit, While Cutting Its Full-Year COVID Vaccine Sales Outlook
12:05pm, Monday, 06'th Nov 2023
BioNTech (BNTX) slashed its outlook for sales of its COVID-19 vaccine, but its American depositary receipts (ADRs) jumped over 4% in early trading Monday after the biotech firm posted a surprise profi
Tesla, Organigram, BioNTech, Dish, Bumble, FreshPet, Berkshire Hathaway – Stocks on the move
09:31am, Monday, 06'th Nov 2023
Dish Network (NASDAQ:DISH), down 10% to $4.94, reported a drop in third-quarter revenue amid declining pay-TV subscribers, triggering a loss for its fiscal third quarter. The US owner of the direct-
BioNTech slashes revenue outlook amid lower Covid vaccine sales
07:23am, Monday, 06'th Nov 2023
BioNTech SE has lowered its forecast for this year's Covid-19 vaccine sales by 20%, becoming the latest drugmaker to adjust its expectations in the post-pandemic era. The German company said it now e
